このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Northeast Pharmaceutical Group マネジメント

マネジメント基準チェック /34

Northeast Pharmaceutical Group'sの CEO はZhou Kaiで、 May2019年に任命され、の在任期間は 5.08年です。は、会社の株式の0.3%を直接所有しており、その価値はCN¥ 17.72M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と4.6年です。

主要情報

Zhou Kai

最高経営責任者

CN¥1.8m

報酬総額

CEO給与比率	n/a
CEO在任期間	5.1yrs
CEOの所有権	0.3%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	4.6yrs

経営陣の近況

Recent updates

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

May 25

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05

CEO（最高経営責任者

Zhou Kai (60 yo)

5.1yrs

在職期間

CN¥1,824,100

報酬

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Zhou Kai	GM & Director	5.1yrs	CN¥1.82m	0.30% CN¥ 16.3m
Jialun Song	Financial Director & Secretary	1.3yrs	CN¥2.14m	0.022% CN¥ 1.2m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	データなし
Wei Zheng	Deputy General Manager	3.3yrs	CN¥890.90k	0.077% CN¥ 4.2m

2.3yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: 000597の経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Zhou Kai	GM & Director	3.6yrs	CN¥1.82m	0.30% CN¥ 16.3m
Demin Han	Independent Director	5.9yrs	CN¥150.00k	データなし
Zhaochun Tan	Non-Independent Director	2.6yrs	データなし	データなし
Chengren Huang	Non-Independent Director	5.9yrs	データなし	0.23% CN¥ 12.5m
Xinhua Ao	Non-Independent Director	5.9yrs	データなし	0.23% CN¥ 12.5m
Guodong Wang	Independent Director	5.9yrs	CN¥150.00k	データなし
Hui Yao	Independent Director	5.9yrs	CN¥150.00k	データなし
Youguang Shang	Independent Director	3.7yrs	CN¥150.00k	データなし
Jianmin Guo	Chairman of the Board	2.7yrs	CN¥2.07m	0.22% CN¥ 12.4m
Zhihua Huang	Non-Independent Director	2.6yrs	データなし	0.070% CN¥ 3.9m
Baidan Zhan	Chairman of the Supervisory Board	5.5yrs	データなし	データなし
Hai Tian	Director	less than a year	データなし	データなし

4.6yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: 000597の取締役会は経験豊富であると考えられます ( 4.6年の平均在任期間)。

Northeast Pharmaceutical Group マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34